系统性硬化症新兴药物与细胞治疗临床试验进展
本文综述系统性硬化症(SSc)在2期和3期临床试验中的新兴药物及部分1/2期细胞治疗试验,重点阐述这些药物靶向的关键疾病机制。文章指出SSc在风湿病中死亡率最高,目前缺乏针对整体疾病的获批疗法,而细胞治疗(包括嵌合抗原受体T细胞疗法)代表重要创新,患者分层和个体化治疗日益受重视。
要点
- SSc在风湿病中死亡率最高,目前缺乏针对整体疾病的获批疗法。
- 过去十年已引入托珠单抗和尼达尼布等器官特异性疗法用于肺纤维化等表现。
- 嵌合抗原受体T细胞疗法等细胞治疗是新兴治疗中的重要创新。
核心结论
- SSc仍缺乏针对整体疾病的获批疗法,但靶向治疗和细胞治疗等新兴策略具有改善预后的潜力。
研究设计与样本
- 本文为综述,回顾当前处于2期和3期临床试验中的药物及部分1/2期细胞治疗试验,并阐述其靶向的关键疾病机制。
主要发现
- 过去十年已引入托珠单抗和尼达尼布等器官特异性疗法管理SSc的不同表现。
- 对SSc发病机制的认识促进可干预分子和细胞通路的识别,推动靶向治疗策略的测试。
- 患者分层和个体化治疗日益受重视,以优化临床试验设计、改善治疗反应性并增强试验结果的普适性。
- 细胞治疗包括嵌合抗原受体T细胞疗法是新兴治疗中的重要创新,可能显著改善SSc结局。
临床怎么用
- 临床可关注2/3期试验中的新兴靶向药物及细胞治疗进展,并重视患者分层与个体化治疗思路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic sclerosis (SSc) is a complex autoimmune disease that affects multiple organs. SSc is associated with the highest mortality rate among rheumatic diseases and significantly diminishes quality of life. Consequently, research efforts have focused on understanding its etiopathogenesis and on developing related targeted therapies. Over the past decade, organ-specific therapies (such as tocilizumab and nintedanib for lung fibrosis) have been introduced to manage various manifestations of SSc. However, there is a lack of approved therapies for the overall disease. Currently, many novel compounds are being further evaluated in ongoing clinical trials. This article reviews drugs currently in phase 2 and phase 3 trials and highlights the key disease mechanisms they target in SSc. Recent advances in understanding the pathogenesis of SSc have facilitated the identification of actionable molecular and cellular pathways, leading to the testing of targeted therapeutic strategies. Concurrently, increasing emphasis is being placed on patient stratification and personalised treatment approaches to optimise clinical trial design, improve treatment responsiveness, and enhance the generalisability of trial outcomes. Among emerging treatments, cellular therapies, including chimeric antigen receptor T-cell therapy, represent a significant innovation. This paradigm shift offers substantial potential for improving outcomes in systemic sclerosis.
引用
- Naveed E, Lescoat A, Matucci-Cerinic M, et al. Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment. Ann Rheum Dis. 2026. PMID: 42919731. doi:10.1016/j.ard.2026.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。